SCHEMBL5158241

SCHEMBL5158241

NCCNC[C@H](CO)NC(=O)OCc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTRB1 P17538 2/20 0.53
ITGB3 P05106 4/20 0.49
ITGA2B P08514 4/20 0.49
SYK P43405 1/20 0.48
PSMB1 P20618 1/20 0.47
PSMB5 P28074 1/20 0.47
PSMB2 P49721 1/20 0.47
HTT P42858 1/20 0.46
CTSK P43235 3/20 0.45
TACR1 P25103 2/20 0.45
PRSS1 P07477 1/20 0.45
PRSS2 P07478 1/20 0.45
PRSS3 P35030 1/20 0.45
TPSAB1 Q15661 1/20 0.45
LMNA P02545 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
CTSL P07711 2/20 0.44
CTSB P07858 1/20 0.44
CTSS P25774 1/20 0.44
ATM Q13315 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20298234 0.84 CTRB1 (0.61) CTRB1ITGB3ITGA2BSYKCTSK
SCHEMBL29641210 0.84 CTRB1 (0.61) CTRB1ITGB3ITGA2BSYKCTSK
SCHEMBL20783325 0.84 CTRB1 (0.61) CTRB1ITGB3ITGA2BSYKCTSK
SCHEMBL29440228 0.84 KYNU (0.56) ITGB3ITGA2BPSMB1PSMB5PSMB2
SCHEMBL4829896 0.83 CTRB1 (0.68) CTRB1SYKCTSKTACR1LMNA
SCHEMBL11668895 0.83 CTRB1 (0.54) CTRB1ITGB3ITGA2BPRSS1PRSS2
SCHEMBL10773754 0.83 CTRB1 (0.54) CTRB1ITGB3ITGA2BPRSS1PRSS2
Hydrochloric Acid SCHEMBL31236441 0.83 CTRB1 (0.57) CTRB1ITGB3ITGA2BSYKCTSK
Hydrochloric Acid SCHEMBL31375007 0.82 KYNU (0.55) ITGB3ITGA2BPSMB1PSMB5PSMB2
Hydrochloric Acid SCHEMBL31376778 0.82 KYNU (0.55) ITGB3ITGA2BPSMB1PSMB5PSMB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7189879-B2 Process for the production of 1-hydroxymethyl-1,3,5-triazapentane, trihydrochloride SCHERING AG (DE) 2007-03-13 US disclosed
EP-1748977-A1 METHOD FOR PRODUCING 1-HYDROXYMETHYL-1,3,5-TRIAZAPENTANE, TRIHYDROCHLORIDE Schering Aktiengesellschaft (DE) 2007-02-07 EP disclosed
US-20060014983-A1 Process for the production of 1-hydroxymethyl-1,3,5-triazapentane, trihydrochloride BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2006-01-19 US disclosed
WO-2005115968-A1 METHOD FOR PRODUCING 1-HYDROXYMETHYL-1,3,5-TRIAZAPENTANE, TRIHYDROCHLORIDE SCHERING AKTIENGESELLSCHAFT (DE) 2005-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014983-A1 Process for the production of 1-hydroxymethyl-1,3,5-triazapentane, trihydrochloride CYP8B1, HADHA, DHPS CTRB1 1472/4885ITGB3 4661/4885ITGA2B 4680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.